Alan C Yeung, MD
Interventional Cardiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yeung’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G65549 · Current
Licensed to practise in California · since 1989 · expires 2027-03-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$142,220
Medicare paid this office $142,220 for 546 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Replacement of aortic valve through the skin and femoral artery | 48 | $29,679 | $618 |
| Return visit (30+ min) | 247 | $27,953 | $73 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 134 | $21,614 | $160 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 32 | $17,132 | $428 |
| Return visit (30+ min) | 62 | $8,662 | $108 |
See all 13 services
| Replacement of aortic valve through the skin and femoral artery | 48 | $29,679 | $618 |
| Return visit (30+ min) | 247 | $27,953 | $73 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 134 | $21,614 | $160 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 32 | $17,132 | $428 |
| Return visit (30+ min) | 62 | $8,662 | $108 |
| New patient visit (45+ min) | 44 | $4,381 | $100 |
| Biopsy of heart muscle | 21 | $3,174 | $151 |
| Insertion of tube in right heart chambers for measurement | 25 | $2,750 | $110 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 22 | $1,732 | $79 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 142 | $1,544 | $11 |
| Short return visit (20+ min) | 23 | $928 | $40 |
| Short return visit (20+ min) | 11 | $833 | $64 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $342 | $20 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 69 | More than 90% of doctors who do this |
Who their Medicare patients are
546 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 19% · Women 38% · Also on Medicaid 25% · Health risk score 1.84. Above the middle of the specialty; the typical interventional cardiology clinician is at 1.7.
Conditions among them: High blood pressure 75% · Coronary heart disease 71% · Heart failure 42% · Chronic kidney disease 42% · Diabetes 40% · Atrial fibrillation 32% · Cancer 16% · COPD 15% · Depression 15% · Stroke 13% · Dementia 8%.
The office billed $1,831,674, Medicare allowed $189,117 and paid $142,220; for 1,095 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 546 | 1,095 | 76 | 1.84 | $1,831,674 | $142,220 |
| 2023 | 758 | 1,295 | 76 | 1.79 | $1,675,877 | $139,969 |
| 2022 | 447 | 913 | 76 | 1.73 | $1,198,044 | $109,061 |
| 2021 | 429 | 874 | 77 | 1.50 | $1,111,380 | $101,297 |
| 2020 | 475 | 919 | 76 | 1.76 | $1,277,127 | $100,462 |
| 2019 | 748 | 1,208 | 75 | 1.87 | $1,120,846 | $106,890 |
| 2018 | 549 | 1,229 | 75 | 1.72 | $1,500,509 | $151,602 |
| 2017 | 725 | 1,372 | 74 | 1.92 | $1,237,500 | $133,980 |
| 2016 | 644 | 1,097 | 75 | 1.83 | $1,411,530 | $151,038 |
| 2015 | 514 | 963 | 74 | 1.73 | $1,141,829 | $139,313 |
| 2014 | 733 | 1,267 | 74 | 1.86 | $684,096 | $97,775 |
| 2013 | 658 | 1,139 | 74 | 1.73 | $523,281 | $75,603 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Replacement of aortic valve through the skin and femoral artery | 59 | $37,735 | $640 |
| Return visit (30+ min) | 227 | $26,193 | $79 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 37 | $19,267 | $419 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 91 | $13,878 | $151 |
| New patient visit (45+ min) | 50 | $5,209 | $104 |
| Short return visit (20+ min) | 85 | $4,127 | $44 |
| Biopsy of heart muscle | 16 | $3,659 | $193 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 249 | $2,154 | $7 |
| Return visit (30+ min) | 14 | $1,753 | $117 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 17 | $1,464 | $81 |
| Insertion of tube in right heart chambers for measurement | 12 | $1,362 | $113 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 106 | $521 | $5 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 18 | $431 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 25 | $275 | $11 |
2022: 13 services
| Replacement of aortic valve through the skin and femoral artery | 40 | $25,955 | $649 |
| Return visit (30+ min) | 190 | $20,188 | $76 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 77 | $13,578 | $176 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 26 | $13,073 | $451 |
| Short return visit (20+ min) | 133 | $7,355 | $46 |
| Biopsy of heart muscle | 26 | $6,706 | $192 |
| New patient visit (45+ min) | 30 | $3,469 | $116 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 15 | $3,308 | $207 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 20 | $1,729 | $82 |
| Insertion of tube in right heart chambers for measurement | 13 | $1,493 | $115 |
| New patient visit (30+ min) | 20 | $1,290 | $64 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 122 | $632 | $5 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $574 | $25 |
2021: 13 services
| Replacement of aortic valve through the skin and femoral artery | 29 | $19,186 | $662 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 82 | $15,001 | $181 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 25 | $13,842 | $447 |
| Short return visit (20+ min) | 207 | $12,619 | $45 |
| Return visit (30+ min) | 125 | $12,414 | $83 |
| Biopsy of heart muscle | 17 | $4,618 | $201 |
| New patient visit (45+ min) | 29 | $3,571 | $123 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $2,221 | $159 |
| New patient visit (30+ min) | 21 | $1,567 | $75 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 100 | $1,158 | $11 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 12 | $1,010 | $84 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 19 | $458 | $24 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $88 | $5 |
2020: 14 services
| Replacement of aortic valve through the skin and femoral artery | 35 | $23,502 | $671 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 83 | $14,302 | $170 |
| Short return visit (20+ min) | 216 | $11,850 | $37 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 22 | $11,032 | $460 |
| Return visit (30+ min) | 68 | $5,557 | $71 |
| Biopsy of heart muscle | 21 | $4,613 | $201 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 19 | $4,266 | $225 |
| New patient visit (30+ min) | 33 | $2,155 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 113 | $1,300 | $11 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 15 | $989 | $66 |
| Return visit (30+ min) | 12 | $852 | $71 |
| Short return visit (20+ min) | 11 | $530 | $41 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 45 | $332 | $7 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $297 | $23 |
2019: 12 services
| Replacement of aortic valve through the skin and femoral artery | 32 | $24,249 | $735 |
| Short return visit (20+ min) | 263 | $17,474 | $40 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 84 | $14,518 | $173 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 23 | $12,859 | $459 |
| Biopsy of heart muscle | 26 | $6,763 | $188 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 16 | $4,120 | $258 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 18 | $3,779 | $210 |
| Insertion of tube in right heart chambers for measurement | 25 | $2,356 | $74 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 294 | $2,196 | $7 |
| New patient visit (45+ min) | 18 | $1,983 | $110 |
| New patient visit (30+ min) | 21 | $1,371 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 95 | $1,062 | $11 |
2018: 13 services
| Replacement of aortic valve through the skin and femoral artery | 48 | $34,695 | $723 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 51 | $26,366 | $425 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 133 | $23,682 | $175 |
| Short return visit (20+ min) | 271 | $18,003 | $39 |
| Biopsy of heart muscle | 39 | $11,810 | $176 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 21 | $5,556 | $265 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 19 | $4,111 | $216 |
| Insertion of tube in right heart chambers for measurement | 29 | $3,612 | $69 |
| New patient visit (30+ min) | 36 | $2,379 | $66 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 195 | $2,254 | $11 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 26 | $1,981 | $76 |
| New patient visit (45+ min) | 11 | $1,133 | $103 |
| Return visit (30+ min) | 11 | $777 | $71 |
2017: 14 services
| Replacement of aortic valve through the skin and femoral artery | 40 | $29,067 | $727 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 104 | $19,122 | $184 |
| Short return visit (20+ min) | 265 | $15,928 | $38 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 28 | $15,350 | $426 |
| Biopsy of heart muscle | 40 | $14,048 | $185 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 19 | $4,871 | $256 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 15 | $3,155 | $210 |
| New patient visit (45+ min) | 23 | $2,426 | $105 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 182 | $2,313 | $11 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 215 | $1,837 | $7 |
| Insertion of tube in right heart chambers for measurement | 23 | $1,698 | $71 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 19 | $1,570 | $83 |
| Return visit (30+ min) | 24 | $1,481 | $57 |
| New patient visit (30+ min) | 22 | $1,409 | $64 |
2016: 12 services
| Replacement of aortic valve through the skin and femoral artery | 43 | $31,209 | $726 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 50 | $29,143 | $435 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 100 | $19,012 | $186 |
| Short return visit (20+ min) | 259 | $15,866 | $37 |
| Biopsy of heart muscle | 30 | $11,498 | $192 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 34 | $9,162 | $269 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 25 | $5,580 | $207 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 26 | $2,148 | $83 |
| Insertion of tube in right heart chambers for measurement | 20 | $1,865 | $89 |
| New patient visit (30+ min) | 28 | $1,712 | $61 |
| Return visit (30+ min) | 20 | $1,471 | $70 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 122 | $1,101 | $7 |
2015: 10 services
| Replacement of aortic valve by through femoral artery | 27 | $21,409 | $793 |
| Short return visit (20+ min) | 288 | $20,070 | $39 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 102 | $19,606 | $192 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 33 | $19,375 | $421 |
| Biopsy of heart muscle | 30 | $13,193 | $194 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 39 | $10,885 | $279 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 17 | $3,950 | $232 |
| Insertion of tube in right heart chambers for measurement | 20 | $1,993 | $74 |
| New patient visit (30+ min) | 26 | $1,628 | $63 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 15 | $1,333 | $83 |
2014: 8 services
| Short return visit (20+ min) | 290 | $20,220 | $39 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 35 | $19,003 | $475 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 68 | $11,935 | $173 |
| Biopsy of heart muscle | 25 | $9,608 | $196 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 34 | $9,340 | $275 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 306 | $3,293 | $8 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 16 | $2,936 | $183 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 17 | $1,353 | $80 |
2013: 11 services
| Short return visit (20+ min) | 284 | $20,365 | $37 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 27 | $14,247 | $475 |
| Insertion of tube in coronary artery for diagnosis with review by radiologist | 67 | $11,448 | $168 |
| Insertion of tube in right heart chambers and coronary artery for diagnosis with review by radiologist | 27 | $7,336 | $272 |
| Biopsy of heart muscle | 15 | $2,429 | $143 |
| Insertion of tube in bypass graft for diagnosis with review by radiologist | 11 | $2,370 | $215 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 235 | $2,346 | $7 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,003 | $77 |
| New patient visit (30+ min) | 12 | $791 | $66 |
| Return visit (30+ min) | 11 | $746 | $62 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $533 | $22 |
Medicaid work
$973 in 2024
Medicaid paid $973 for 31 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 31 | $973 |
| 2024 | 31 | 1 | 16 | $973 |
| 2023 | 243 | 2 | 103 | $2,821 |
| 2020 | 44 | 1 | 42 | $509 |
| 2019 | 174 | 2 | 59 | $2,250 |
| 2018 | 14 | 1 | 14 | $210 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 230 | $2,327 |
| Return visit (30+ min) | 13 | $494 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 44 | $509 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 149 | $1,881 |
| Short return visit (20+ min) | 25 | $368 |
2018
| Short return visit (20+ min) | 14 | $210 |
Drugs they prescribed that Part D paid
$409,585
Pharmacies billed $409,585 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,688) in 2024. At or below the middle of the specialty; the typical interventional cardiology clinician is at 0%.
2,347 generic and 341 brand-name prescriptions · $409,585 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 60 | $82,558 | $1,376 |
| Entresto | 57 | $71,326 | $1,251 |
| Repatha Sureclick | 64 | $65,164 | $1,018 |
| Jardiance | 25 | $42,588 | $1,704 |
| Brilinta | 13 | $13,658 | $1,051 |
See all 37 drugs
| Eliquis | 60 | $82,558 | $1,376 |
| Entresto | 57 | $71,326 | $1,251 |
| Repatha Sureclick | 64 | $65,164 | $1,018 |
| Jardiance | 25 | $42,588 | $1,704 |
| Brilinta | 13 | $13,658 | $1,051 |
| Ozempic | 11 | $10,484 | $953 |
| Repatha | 11 | $5,951 | $541 |
| Rosuvastatin | 276 | $5,525 | $20 |
| Vascepa | 11 | $4,593 | $418 |
| Ezetimibe | 152 | $4,158 | $27 |
| Icosapent Ethyl | 18 | $3,822 | $212 |
| Metoprolol | 238 | $3,820 | $16 |
| Atorvastatin | 324 | $2,718 | $8 |
| Clopidogrel | 141 | $2,402 | $17 |
| Ranolazine Er | 39 | $2,152 | $55 |
| Valsartan | 53 | $1,540 | $29 |
| Isosorbide Mononitrate Er | 60 | $1,215 | $20 |
| Irbesartan | 32 | $1,165 | $36 |
| Omega-3 Acid Ethyl Esters | 12 | $960 | $80 |
| Potassium Chloride | 28 | $857 | $31 |
| Losartan | 98 | $816 | $8 |
| Nitroglycerin | 43 | $809 | $19 |
| Lisinopril | 93 | $792 | $9 |
| Carvedilol | 54 | $789 | $15 |
| Amlodipine Besylate | 120 | $709 | $6 |
| Diltiazem 24hr Er (Cd) | 19 | $595 | $31 |
| Simvastatin | 54 | $562 | $10 |
| Furosemide | 75 | $491 | $7 |
| Spironolactone | 44 | $436 | $10 |
| Valsartan-Hydrochlorothiazide | 15 | $399 | $27 |
| Chlorthalidone | 20 | $360 | $18 |
| Atenolol | 48 | $360 | $7 |
| Bisoprolol | 12 | $248 | $21 |
| Hydrochlorothiazide | 58 | $191 | $3 |
| Diltiazem | 13 | $168 | $13 |
| Metoprolol | 29 | $111 | $4 |
| Ezetimibe-Simvastatin | 11 | $104 | $9 |
Year by year
| 2024 | 2,688 | 339 | 0% (0) | 13% | $409,585 |
| 2023 | 2,503 | 309 | 0% (0) | None | $379,143 |
| 2022 | 2,314 | 290 | 0% (0) | 12% | $297,955 |
| 2021 | 2,001 | 261 | 0% (0) | 13% | $258,187 |
| 2020 | 1,969 | 251 | 0% (0) | 12% | $183,374 |
| 2019 | 2,104 | 282 | 0% (0) | 12% | $188,195 |
| 2018 | 2,257 | 313 | 0% (0) | 13% | $219,340 |
| 2017 | 2,423 | 321 | 0% (0) | 17% | $247,259 |
| 2016 | 2,457 | 276 | 0% (0) | 23% | $258,799 |
| 2015 | 2,519 | 276 | 0% (0) | 26% | $248,216 |
| 2014 | 2,313 | 245 | None | 27% | $207,896 |
| 2013 | 2,329 | 209 | None | None | $221,013 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Eliquis | 62 | $81,097 | $1,308 |
| Repatha Sureclick | 40 | $41,001 | $1,025 |
| Entresto | 22 | $35,457 | $1,612 |
| Jardiance | 21 | $29,427 | $1,401 |
| Praluent | 27 | $27,425 | $1,016 |
| Brilinta | 14 | $18,121 | $1,294 |
| Ezetimibe | 131 | $10,055 | $77 |
| Vascepa | 14 | $9,418 | $673 |
| Repatha | 12 | $7,058 | $588 |
| Rosuvastatin | 207 | $6,865 | $33 |
| Metoprolol | 231 | $6,036 | $26 |
| Ranolazine Er | 23 | $5,851 | $254 |
| Atorvastatin | 328 | $4,941 | $15 |
| Icosapent Ethyl | 16 | $4,711 | $294 |
| Valsartan | 67 | $3,880 | $58 |
| Clopidogrel | 146 | $2,816 | $19 |
| Isosorbide Mononitrate Er | 82 | $2,468 | $30 |
| Amlodipine Besylate | 106 | $1,806 | $17 |
| Losartan | 94 | $1,690 | $18 |
| Lisinopril | 87 | $1,204 | $14 |
| Carvedilol | 65 | $1,171 | $18 |
| Nitroglycerin | 42 | $1,013 | $24 |
| Diltiazem 24hr Er (Cd) | 23 | $898 | $39 |
| Atenolol | 42 | $809 | $19 |
| Irbesartan | 31 | $766 | $25 |
| Bisoprolol | 15 | $751 | $50 |
| Potassium Chloride | 15 | $670 | $45 |
| Furosemide | 80 | $664 | $8 |
| Chlorthalidone | 11 | $549 | $50 |
| Simvastatin | 53 | $532 | $10 |
| Metoprolol | 40 | $483 | $12 |
| Spironolactone | 34 | $419 | $12 |
| Hydrochlorothiazide | 56 | $249 | $4 |
| Warfarin | 11 | $240 | $22 |
2022: 35 drugs
| Eliquis | 39 | $57,566 | $1,476 |
| Repatha Sureclick | 30 | $27,495 | $917 |
| Jardiance | 27 | $23,927 | $886 |
| Praluent | 17 | $17,598 | $1,035 |
| Entresto | 13 | $15,461 | $1,189 |
| Vascepa | 16 | $13,102 | $819 |
| Repatha | 23 | $12,007 | $522 |
| Brilinta | 11 | $11,179 | $1,016 |
| Rosuvastatin | 180 | $9,539 | $53 |
| Ranolazine Er | 35 | $9,350 | $267 |
| Ezetimibe | 85 | $7,729 | $91 |
| Metoprolol | 216 | $4,708 | $22 |
| Atorvastatin | 325 | $4,161 | $13 |
| Clopidogrel | 154 | $2,637 | $17 |
| Olmesartan Medoxomil | 11 | $2,387 | $217 |
| Valsartan | 38 | $2,223 | $59 |
| Isosorbide Mononitrate Er | 58 | $1,360 | $23 |
| Losartan | 78 | $1,275 | $16 |
| Bisoprolol | 13 | $1,176 | $90 |
| Carvedilol | 71 | $1,157 | $16 |
| Irbesartan | 30 | $1,130 | $38 |
| Amlodipine Besylate | 104 | $919 | $9 |
| Nitroglycerin | 41 | $872 | $21 |
| Lisinopril | 72 | $619 | $9 |
| Furosemide | 105 | $587 | $6 |
| Diltiazem 24hr Er (Cd) | 15 | $461 | $31 |
| Simvastatin | 63 | $395 | $6 |
| Diltiazem | 16 | $384 | $24 |
| Atenolol | 49 | $328 | $7 |
| Spironolactone | 22 | $324 | $15 |
| Omeprazole | 13 | $312 | $24 |
| Potassium Chloride | 12 | $296 | $25 |
| Hydrochlorothiazide | 60 | $286 | $5 |
| Metoprolol | 31 | $152 | $5 |
| Donepezil Hcl Odt | 12 | $126 | $11 |
2021: 34 drugs
| Eliquis | 40 | $49,338 | $1,233 |
| Brilinta | 19 | $18,741 | $986 |
| Vascepa | 22 | $18,138 | $824 |
| Repatha Sureclick | 26 | $16,073 | $618 |
| Entresto | 14 | $13,670 | $976 |
| Praluent | 18 | $12,573 | $699 |
| Ranolazine Er | 35 | $7,465 | $213 |
| Repatha | 12 | $6,991 | $583 |
| Ezetimibe | 71 | $5,788 | $82 |
| Rosuvastatin | 137 | $5,253 | $38 |
| Atorvastatin | 282 | $4,559 | $16 |
| Metoprolol | 167 | $4,185 | $25 |
| Valsartan | 46 | $3,479 | $76 |
| Clopidogrel | 146 | $2,456 | $17 |
| Telmisartan | 23 | $1,980 | $86 |
| Valsartan-Hydrochlorothiazide | 14 | $1,418 | $101 |
| Isosorbide Mononitrate Er | 48 | $1,188 | $25 |
| Irbesartan | 26 | $983 | $38 |
| Nitroglycerin | 28 | $968 | $35 |
| Fenofibrate | 11 | $851 | $77 |
| Amlodipine Besylate | 78 | $851 | $11 |
| Carvedilol | 58 | $825 | $14 |
| Losartan | 51 | $770 | $15 |
| Diltiazem 24hr Er (Cd) | 14 | $655 | $47 |
| Lisinopril | 63 | $610 | $10 |
| Simvastatin | 71 | $600 | $8 |
| Donepezil Hcl Odt | 12 | $563 | $47 |
| Atenolol | 47 | $519 | $11 |
| Furosemide | 84 | $477 | $6 |
| Spironolactone | 15 | $302 | $20 |
| Potassium Chloride | 13 | $289 | $22 |
| Hydrochlorothiazide | 52 | $234 | $4 |
| Warfarin | 15 | $109 | $7 |
| Metoprolol | 30 | $95 | $3 |
2020: 29 drugs
| Eliquis | 17 | $22,888 | $1,346 |
| Brilinta | 12 | $11,905 | $992 |
| Vascepa | 17 | $10,556 | $621 |
| Repatha Sureclick | 15 | $8,644 | $576 |
| Rosuvastatin | 124 | $6,771 | $55 |
| Repatha | 13 | $6,143 | $473 |
| Praluent | 13 | $6,042 | $465 |
| Atorvastatin | 343 | $5,653 | $16 |
| Ezetimibe | 61 | $5,318 | $87 |
| Metoprolol | 152 | $3,919 | $26 |
| Valsartan | 49 | $3,117 | $64 |
| Ranolazine Er | 17 | $2,882 | $170 |
| Clopidogrel | 157 | $2,094 | $13 |
| Irbesartan | 31 | $1,504 | $49 |
| Nitroglycerin | 42 | $1,499 | $36 |
| Isosorbide Mononitrate Er | 39 | $1,089 | $28 |
| Carvedilol | 57 | $900 | $16 |
| Amlodipine Besylate | 78 | $699 | $9 |
| Lisinopril | 73 | $692 | $9 |
| Atenolol | 46 | $645 | $14 |
| Losartan | 57 | $605 | $11 |
| Furosemide | 94 | $584 | $6 |
| Simvastatin | 61 | $534 | $9 |
| Diltiazem 24hr Er (Cd) | 13 | $458 | $35 |
| Hydrochlorothiazide | 52 | $362 | $7 |
| Potassium Chloride | 15 | $310 | $21 |
| Donepezil Hcl Odt | 12 | $247 | $21 |
| Spironolactone | 12 | $150 | $13 |
| Metoprolol | 24 | $115 | $5 |
2019: 37 drugs
| Eliquis | 23 | $25,804 | $1,122 |
| Praluent | 17 | $18,760 | $1,104 |
| Brilinta | 12 | $12,603 | $1,050 |
| Repatha Sureclick | 16 | $8,712 | $545 |
| Rosuvastatin | 126 | $7,392 | $59 |
| Ezetimibe | 59 | $6,970 | $118 |
| Repatha | 12 | $6,371 | $531 |
| Ranolazine Er | 23 | $6,270 | $273 |
| Atorvastatin | 339 | $6,204 | $18 |
| Vascepa | 18 | $5,911 | $328 |
| Metoprolol | 159 | $5,592 | $35 |
| Clopidogrel | 176 | $2,927 | $17 |
| Valsartan | 43 | $2,236 | $52 |
| Toprol Xl | 11 | $1,934 | $176 |
| Irbesartan | 34 | $1,722 | $51 |
| Isosorbide Mononitrate Er | 42 | $1,171 | $28 |
| Carvedilol | 71 | $1,082 | $15 |
| Nitroglycerin | 35 | $1,000 | $29 |
| Valsartan-Hydrochlorothiazide | 14 | $799 | $57 |
| Amlodipine Besylate | 79 | $736 | $9 |
| Atenolol | 56 | $730 | $13 |
| Simvastatin | 75 | $717 | $10 |
| Lisinopril | 82 | $642 | $8 |
| Hydralazine | 13 | $628 | $48 |
| Losartan | 53 | $625 | $12 |
| Potassium Chloride | 16 | $616 | $38 |
| Furosemide | 80 | $587 | $7 |
| Diltiazem 24hr Er (Cd) | 15 | $429 | $29 |
| Losartan-Hydrochlorothiazide | 16 | $261 | $16 |
| Hydrochlorothiazide | 37 | $246 | $7 |
| Spironolactone | 14 | $234 | $17 |
| Levothyroxine | 18 | $221 | $12 |
| Metoprolol | 34 | $212 | $6 |
| Warfarin | 13 | $197 | $15 |
| Donepezil Hcl Odt | 11 | $192 | $17 |
| Fosinopril | 12 | $88 | $7 |
| Metformin | 12 | $47 | $4 |
2018: 37 drugs
| Brilinta | 36 | $28,768 | $799 |
| Praluent | 22 | $25,501 | $1,159 |
| Eliquis | 21 | $22,853 | $1,088 |
| Ranexa | 14 | $14,160 | $1,011 |
| Ezetimibe | 66 | $12,692 | $192 |
| Xarelto | 11 | $10,212 | $928 |
| Atorvastatin | 356 | $7,068 | $20 |
| Rosuvastatin | 120 | $6,571 | $55 |
| Ezetimibe-Simvastatin | 12 | $5,280 | $440 |
| Vascepa | 16 | $5,072 | $317 |
| Plavix | 11 | $4,877 | $443 |
| Metoprolol | 153 | $4,338 | $28 |
| Clopidogrel | 217 | $3,170 | $15 |
| Irbesartan | 46 | $1,873 | $41 |
| Isosorbide Mononitrate Er | 63 | $1,411 | $22 |
| Valsartan | 40 | $1,352 | $34 |
| Carvedilol | 76 | $1,042 | $14 |
| Nitroglycerin | 33 | $983 | $30 |
| Lisinopril | 101 | $880 | $9 |
| Simvastatin | 92 | $861 | $9 |
| Atenolol | 58 | $729 | $13 |
| Potassium Chloride | 16 | $726 | $45 |
| Olmesartan Medoxomil | 12 | $632 | $53 |
| Amlodipine Besylate | 64 | $539 | $8 |
| Diltiazem 24hr Er (Cd) | 13 | $499 | $38 |
| Losartan | 49 | $488 | $10 |
| Furosemide | 71 | $473 | $7 |
| Valsartan-Hydrochlorothiazide | 17 | $396 | $23 |
| Warfarin | 19 | $388 | $20 |
| Metoprolol | 47 | $295 | $6 |
| Losartan-Hydrochlorothiazide | 16 | $284 | $18 |
| Spironolactone | 18 | $259 | $14 |
| Hydrochlorothiazide | 28 | $173 | $6 |
| Levothyroxine | 14 | $168 | $12 |
| Donepezil Hcl Odt | 12 | $131 | $11 |
| Fosinopril | 12 | $59 | $5 |
| Metformin | 11 | $37 | $3 |
2017: 37 drugs
| Zetia | 45 | $31,631 | $703 |
| Praluent | 18 | $20,892 | $1,161 |
| Ranexa | 27 | $17,004 | $630 |
| Brilinta | 19 | $16,844 | $887 |
| Crestor | 21 | $11,141 | $531 |
| Ezetimibe | 41 | $8,053 | $196 |
| Rosuvastatin | 112 | $6,790 | $61 |
| Atorvastatin | 332 | $6,558 | $20 |
| Effient | 14 | $5,956 | $425 |
| Metoprolol | 157 | $4,798 | $31 |
| Vascepa | 14 | $4,666 | $333 |
| Clopidogrel | 275 | $3,967 | $14 |
| Valsartan | 55 | $2,239 | $41 |
| Isosorbide Mononitrate Er | 85 | $2,050 | $24 |
| Nitroglycerin | 31 | $1,672 | $54 |
| Irbesartan | 28 | $1,468 | $52 |
| Simvastatin | 107 | $1,017 | $10 |
| Nitrostat | 15 | $866 | $58 |
| Fenofibrate | 13 | $799 | $61 |
| Enalapril Maleate | 17 | $769 | $45 |
| Lisinopril | 114 | $762 | $7 |
| Atenolol | 62 | $722 | $12 |
| Diltiazem 24hr Er | 20 | $717 | $36 |
| Potassium Chloride | 16 | $686 | $43 |
| Carvedilol | 69 | $668 | $10 |
| Warfarin | 38 | $527 | $14 |
| Amlodipine Besylate | 65 | $517 | $8 |
| Valsartan-Hydrochlorothiazide | 19 | $471 | $25 |
| Furosemide | 78 | $457 | $6 |
| Losartan | 53 | $413 | $8 |
| Metoprolol | 80 | $408 | $5 |
| Omeprazole | 12 | $392 | $33 |
| Spironolactone | 18 | $323 | $18 |
| Losartan-Hydrochlorothiazide | 22 | $287 | $13 |
| Hydrochlorothiazide | 32 | $206 | $6 |
| Levothyroxine | 12 | $151 | $13 |
| Lisinopril-Hydrochlorothiazide | 11 | $64 | $6 |
2016: 36 drugs
| Zetia | 69 | $40,893 | $593 |
| Crestor | 101 | $38,301 | $379 |
| Ranexa | 27 | $20,712 | $767 |
| Vytorin | 28 | $20,620 | $736 |
| Effient | 16 | $8,837 | $552 |
| Plavix | 17 | $7,457 | $439 |
| Atorvastatin | 293 | $6,487 | $22 |
| Benicar | 13 | $5,840 | $449 |
| Metoprolol | 201 | $5,822 | $29 |
| Omega-3 Acid Ethyl Esters | 24 | $5,699 | $237 |
| Clopidogrel | 309 | $5,441 | $18 |
| Rosuvastatin | 29 | $4,673 | $161 |
| Isosorbide Mononitrate Er | 88 | $1,754 | $20 |
| Nitrostat | 38 | $1,579 | $42 |
| Valsartan | 48 | $1,421 | $30 |
| Fenofibrate | 16 | $1,301 | $81 |
| Enalapril Maleate | 25 | $1,243 | $50 |
| Diltiazem 24hr Er | 23 | $1,083 | $47 |
| Atenolol | 85 | $1,046 | $12 |
| Simvastatin | 96 | $930 | $10 |
| Irbesartan | 31 | $906 | $29 |
| Lisinopril | 94 | $876 | $9 |
| Omeprazole | 23 | $829 | $36 |
| Potassium Chloride | 13 | $786 | $60 |
| Carvedilol | 71 | $748 | $11 |
| Losartan | 59 | $678 | $11 |
| Furosemide | 73 | $556 | $8 |
| Valsartan-Hydrochlorothiazide | 18 | $518 | $29 |
| Warfarin | 36 | $444 | $12 |
| Amlodipine Besylate | 78 | $434 | $6 |
| Metoprolol | 65 | $423 | $7 |
| Losartan-Hydrochlorothiazide | 24 | $247 | $10 |
| Hydrochlorothiazide | 35 | $206 | $6 |
| Spironolactone | 12 | $165 | $14 |
| Lisinopril-Hydrochlorothiazide | 13 | $94 | $7 |
| Clonidine | 11 | $80 | $7 |
2015: 40 drugs
| Crestor | 129 | $45,247 | $351 |
| Zetia | 64 | $31,200 | $487 |
| Vytorin | 41 | $24,277 | $592 |
| Ranexa | 27 | $18,279 | $677 |
| Nexium | 17 | $12,463 | $733 |
| Plavix | 24 | $7,299 | $304 |
| Atorvastatin | 264 | $6,309 | $24 |
| Diovan | 11 | $6,295 | $572 |
| Effient | 13 | $6,111 | $470 |
| Metoprolol | 184 | $5,654 | $31 |
| Omega-3 Acid Ethyl Esters | 24 | $5,631 | $235 |
| Clopidogrel | 297 | $4,497 | $15 |
| Lipitor | 14 | $3,802 | $272 |
| Valsartan | 39 | $2,628 | $67 |
| Enalapril Maleate | 39 | $1,930 | $49 |
| Isosorbide Mononitrate Er | 83 | $1,759 | $21 |
| Nitrostat | 61 | $1,643 | $27 |
| Isosorbide Dinitrate | 14 | $1,045 | $75 |
| Taztia Xt | 17 | $966 | $57 |
| Atenolol | 81 | $846 | $10 |
| Simvastatin | 83 | $757 | $9 |
| Diltiazem 24hr Er | 19 | $746 | $39 |
| Lisinopril | 100 | $740 | $7 |
| Carvedilol | 69 | $689 | $10 |
| Losartan | 67 | $679 | $10 |
| Amlodipine Besylate | 79 | $669 | $8 |
| Omeprazole | 21 | $626 | $30 |
| Valsartan-Hydrochlorothiazide | 20 | $608 | $30 |
| Irbesartan | 25 | $603 | $24 |
| Furosemide | 82 | $585 | $7 |
| Metoprolol | 70 | $576 | $8 |
| Cartia Xt | 12 | $552 | $46 |
| Potassium Chloride | 13 | $468 | $36 |
| Losartan-Hydrochlorothiazide | 22 | $312 | $14 |
| Ramipril | 16 | $284 | $18 |
| Pantoprazole | 12 | $282 | $23 |
| Hydrochlorothiazide | 48 | $263 | $5 |
| Benazepril | 11 | $96 | $9 |
| Clonidine | 13 | $83 | $6 |
| Lisinopril-Hydrochlorothiazide | 19 | $78 | $4 |
2014: 41 drugs
| Zetia | 68 | $25,229 | $371 |
| Vytorin | 40 | $20,419 | $510 |
| Nexium | 27 | $19,739 | $731 |
| Crestor | 64 | $19,262 | $301 |
| Diovan | 42 | $14,847 | $354 |
| Lovaza | 22 | $11,089 | $504 |
| Ranexa | 14 | $9,208 | $658 |
| Plavix | 18 | $8,707 | $484 |
| Atorvastatin | 281 | $7,074 | $25 |
| Metoprolol | 170 | $6,711 | $39 |
| Effient | 16 | $5,466 | $342 |
| Niacin Er | 12 | $5,130 | $428 |
| Clopidogrel | 253 | $4,903 | $19 |
| Benicar | 12 | $2,550 | $212 |
| Isosorbide Mononitrate Er | 126 | $1,978 | $16 |
| Irbesartan | 21 | $1,934 | $92 |
| Diltiazem 24hr Er | 25 | $1,271 | $51 |
| Simvastatin | 103 | $1,113 | $11 |
| Valsartan-Hydrochlorothiazide | 14 | $992 | $71 |
| Nitrostat | 47 | $981 | $21 |
| Losartan | 69 | $975 | $14 |
| Amlodipine Besylate | 72 | $860 | $12 |
| Omeprazole | 34 | $777 | $23 |
| Taztia Xt | 13 | $761 | $59 |
| Atenolol | 78 | $757 | $10 |
| Lisinopril | 75 | $657 | $9 |
| Carvedilol | 55 | $649 | $12 |
| Metoprolol | 49 | $524 | $11 |
| Potassium Chloride | 19 | $477 | $25 |
| Enalapril Maleate | 26 | $430 | $17 |
| Furosemide | 69 | $409 | $6 |
| Hydrochlorothiazide | 41 | $382 | $9 |
| Ramipril | 22 | $377 | $17 |
| Warfarin | 15 | $315 | $21 |
| Pantoprazole | 11 | $269 | $24 |
| Losartan-Hydrochlorothiazide | 11 | $267 | $24 |
| Zolpidem | 12 | $169 | $14 |
| Clonidine | 13 | $100 | $8 |
| Indapamide | 13 | $83 | $6 |
| Lisinopril-Hydrochlorothiazide | 12 | $83 | $7 |
| Metoclopramide | 13 | $65 | $5 |
2013: 41 drugs
| Vytorin | 57 | $23,192 | $407 |
| Zetia | 70 | $20,885 | $298 |
| Crestor | 70 | $19,749 | $282 |
| Nexium | 38 | $19,448 | $512 |
| Diovan | 53 | $18,770 | $354 |
| Niaspan | 26 | $12,413 | $477 |
| Clopidogrel | 252 | $11,940 | $47 |
| Plavix | 30 | $10,397 | $347 |
| Atorvastatin | 235 | $10,099 | $43 |
| Ranexa | 16 | $8,990 | $562 |
| Lovaza | 23 | $8,147 | $354 |
| Metoprolol | 131 | $7,422 | $57 |
| Fenofibrate | 11 | $3,571 | $325 |
| Isosorbide Mononitrate Er | 104 | $2,393 | $23 |
| Valsartan-Hydrochlorothiazide | 11 | $2,289 | $208 |
| Irbesartan | 14 | $2,110 | $151 |
| Diltiazem 24hr Er | 28 | $1,568 | $56 |
| Simvastatin | 135 | $1,483 | $11 |
| Amlodipine Besylate | 85 | $964 | $11 |
| Atenolol | 82 | $901 | $11 |
| Losartan-Hydrochlorothiazide | 20 | $876 | $44 |
| Losartan | 47 | $841 | $18 |
| Fenofibrate | 12 | $822 | $68 |
| Nitrostat | 38 | $715 | $19 |
| Carvedilol | 53 | $711 | $13 |
| Lisinopril | 80 | $683 | $9 |
| Omeprazole | 33 | $649 | $20 |
| Ramipril | 21 | $623 | $30 |
| Tamsulosin | 14 | $612 | $44 |
| Diltiazem 24hr Cd | 17 | $572 | $34 |
| Furosemide | 88 | $466 | $5 |
| Warfarin | 24 | $420 | $18 |
| Potassium Chloride | 19 | $411 | $22 |
| Metoprolol | 36 | $366 | $10 |
| Hydrochlorothiazide | 46 | $316 | $7 |
| Zolpidem | 28 | $167 | $6 |
| Alprazolam | 12 | $155 | $13 |
| Clonidine | 13 | $119 | $9 |
| Lisinopril-Hydrochlorothiazide | 13 | $110 | $8 |
| Enalapril Maleate | 12 | $96 | $8 |
| Indapamide | 13 | $47 | $4 |
Money from drug and device companies
$3,431 in 2025
| 2025 | 3 | 9 | $1,500 | $3,431 |
| 2024 | 5 | 11 | $7,288 | $7,906 |
| 2023 | 5 | 7 | None | $629 |
| 2022 | 3 | 28 | $14,150 | $18,516 |
| 2021 | 4 | 40 | $5,350 | $9,120 |
| 2020 | 2 | 13 | $8,200 | $9,522 |
| 2019 | 7 | 37 | $13,200 | $29,738 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Histosonics | None | $1,561 | 1 payment
|
| Cordis US | Emerald | $1,538 | 2 payments
|
| Medtronic | Corevalve Evolut R | $333 | 3 payments
|
See all 6 published payments
| Cordis US | Travel · 2025-11-21 | Emerald | $38 |
| Cordis US | Consulting · 2025-11-21 | Emerald | $1,500 |
| Histosonics | Travel · 2025-10-30 | None | $1,561 |
| Medtronic | Meals · 2025-10-26 | Corevalve Evolut R | $42 |
| Medtronic | Meals · 2025-06-27 | Corevalve Evolut R | $119 |
| Medtronic | Meals · 2025-06-26 | Corevalve Evolut R | $172 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,906
| Boston Scientific | None | $4,688 | 3 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $2,822 | 2 payments
|
| Medtronic | Corevalve Evolut R | $277 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $75 | 1 payment
|
| Cardiva Medical | Savvywire | $45 | 1 payment
|
2023: $629
| Boston Scientific | None | $165 | 1 payment
|
| Medtronic | Corevalve Evolut R | $150 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $140 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $100 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $74 | 1 payment
|
2022: $18,516
| Boston Scientific | General - Therapies | $10,891 | 12 payments
|
| Medtronic | Resolute Onyx | $6,684 | 15 payments
|
| Edwards Lifesciences | None | $940 | 1 payment
|
2021: $9,120
| Boston Scientific | General Vascular Access | $4,000 | 1 payment
|
| Medtronic | Resolute | $3,420 | 21 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $1,381 | 13 payments
|
| Abbott Laboratories | Amplatzer Vascular Plug and Accs | $319 | 5 payments
|
2020: $9,522
| Medtronic Vascular | Resolute | $7,322 | 12 payments
|
| Boston Scientific | General - Vascular Access | $2,200 | 1 payment
|
2019: $29,738
| Philips Electronics North America | Igt Systems Und | $11,496 | 3 payments
|
| Boston Scientific | General Vascular Access | $9,291 | 11 payments
|
| Medtronic Vascular | Resolute | $8,507 | 18 payments
|
| Ge Healthcare | None | $210 | 1 payment
|
| Abbott Laboratories | Mitra Clip System | $149 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $72 | 1 payment
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $12 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Edwards Lifesciences Corporation · The Progress Trial – Continued Access 2021-01-Cap · 2025 | Their institution | $125,373 |
| Abbott Laboratories · A Clinical Evaluation of Absorb Bvs, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With De Novo Native Coronary Artery Lesions · 2022 | Their institution | $13,835 |
| Medtronic Vascular, Inc. · Corevalve Surtavi · 2019 | Their institution | $12,079 |
| Abbott Laboratories · A Clinical Evaluation of Absorb Bvs, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With De Novo Native Coronary Artery Lesions. · 2019 | Their institution | $7,875 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (the Coapt Trial) and Coapt Cas (Coapt) · 2024 | Their institution | $4,972 |
| Medtronic Vascular, Inc. · Corevalve Surtavi · 2020 | Their institution | $4,791 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation · 2020 | Their institution | $4,500 |
| Medtronic, Inc. · Corevalve Surtavi · 2021 | Their institution | $4,333 |
| Abbott Laboratories · A Clinical Evaluation of Absorb Bvs, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With De Novo Native Coronary Artery Lesions. · 2021 | Their institution | $4,025 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mr (Coapt) Continued Access Study · 2020 | Their institution | $4,000 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (the Coapt Trial) and Coapt Cas (Coapt) · 2023 | Their institution | $3,508 |
| Abbott Laboratories · Absorb III Randomized Controlled Trial (Rct) (Absorb-III) · 2020 | Their institution | $2,300 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation · 2019 | Their institution | $2,100 |
| Abbott Laboratories · Ardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (the Coapt Trial) (Coapt) · 2019 | Their institution | $1,750 |
| Medtronic, Inc. · Corevalve Surtavi · 2025 | Their institution | $1,369 |
| Medtronic, Inc. · Corevalve Surtavi · 2024 | Their institution | $1,280 |
| Abbott Laboratories · Cardiovascular Outcomes Assessment of the Mitraclip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (the Coapt Trial) · 2020 | Their institution | $900 |
| Medtronic, Inc. · Corevalve Surtavi · 2022 | Their institution | $640 |
| Abbott Laboratories · Coapt Continued Access Study · 2021 | Their institution | $300 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1700920139
- Licence
- CA G65549California G65549: Current · expires 2027-03-31
- Trained
- Harvard Medical School, 1984
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-18
- NPI last updated
- 2024-04-27
- NPI record certified
- 2024-04-27
This is when the NPI record was last certified, not a medical board exam.